Aging associated loss of muscle mass leads to metabolic diseases and compromised quality of life. Increase in intramyocellular lipid (IMCL) and reduced skeletal muscle mass are associated with insulin resistance and diabetes. Rapamycin increases muscle mass by inhibiting the mTOR signalling pathway. In this study, we investigated IMCL metabolism and muscle mass in response to rapamycin intervention in an aging rodent model. We observed significant reduction in IMCL along with increase in muscle mass indicating improved muscle metabolism with rapamycin intervention. Muscle differentiation gene, MyoD was upregulated and myostatin which is negative regulator of muscle growth factor was down regulated.